NCT07299942 Impact of Beta-glucan Supplementation During Calorie and Carbohydrate-restricted Diet on Body Weight and Body Fat Loss, Appetite, and Gastrointestinal Appetite Hormones.
| NCT ID | NCT07299942 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Glasgow |
| Condition | Overweight and Obese Women |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-07-01 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate whether beta-glucan supplementation, when added to an energy and carbohydrate-restricted diet, facilitates body weight and body fat loss, and leads to less detrimental changes in subjective appetite and gastrointestinal appetite hormones. This will be a double-blind, randomised, controlled trial in which healthy females living with overweight and obesity will be randomly assigned to a beta-glucan or a cellulose (placebo) group (1:1 basis). The randomisation software will be used to generate a randomisation list. This list will be held by a person independent of the research team. During the 4-week intervention, participants will consume an energy and carbohydrate-restricted diet combined with 9 g/day of beta-glucan (beta-glucan group) or 9 g/day of cellulose (Placebo group). During the 4-week intervention, breakfasts and dinners will consist of energy-restricted meal replacements providing 200 kcal/ meal, while lunches will be low-carbohydrate meals providing 35% of habitual energy intake. Before and at the end of the intervention, participants will conduct an experimental trial, with pre- and post-intervention trials being identical. The experimental trials will take place in the metabolic room of the New Lister Building (NLB) of the Glasgow Royal Infirmary. During the experimental trials, body weight and body composition will be measured in the fasted state, and the collection of fasting and postprandial (for the duration of 240 minutes) blood samples will be conducted. For a meal, participants will consume the low-calorie breakfast, which will be a liquid meal replacement (Cambridge Weight Plan, Corby, UK), together with 3 g of beta-glucan. Subjective appetite scores will be measured in the fasted and postprandial states. To achieve total body water and thus body composition (fat mass and fat-free mass) measurements, saliva will be collected before and 3 and 3.5 hours after consumption of D2O (which will be consumed in the fasted state). For the duration of 24 hours before the experimental trial, participants will be asked to avoid coffee and alcohol. Participants will be required to record their food and drink intake for three days before the trial days of each experimental investigation.
Eligibility Criteria
Inclusion Criteria: * Healthy females living with overweight or obese (BMI of 25 - 39.9 kg/m2). * Age between 18 to 60 years. * Stable body weight for at least 3 months preceding the study. Exclusion Criteria: * Smokers * Irregular menstrual cycle * Exercising more than 75min a week * Pregnant or lactating * Food allergies * Vegan or vegetarian or follow any diet other than the typical Western diet. * Taking dietary supplement at the time of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07299942 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 60 Years, studying Overweight and Obese Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07299942 currently recruiting?
Yes, NCT07299942 is actively recruiting participants. Contact the research team at Dalia.Malkova@glasgow.ac.uk for enrollment information.
Where is the NCT07299942 trial being conducted?
This trial is being conducted at Glasgow, United Kingdom.
Who is sponsoring the NCT07299942 clinical trial?
NCT07299942 is sponsored by University of Glasgow. The trial plans to enroll 60 participants.